Secondary outcomes in conbercept and ranibizumab groups over 1 year.... | Download Scientific Diagram
Anti-VEGF: Where Are We Now?
Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis | SpringerLink
The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review. - Document - Gale Academic OneFile
Phase III Trials in Wet AMD—What's Next?
Emerging Treatments for Neovascular AMD - Retina Today
More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept
The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review
New Drugs in the Pipeline for the Management of AMD | IntechOpen
An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma | Eye
IJMS | Free Full-Text | Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
Age-Related Macular Degeneration - Retina Research - Retina Associates
Emerging Treatments for Neovascular AMD - Retina Today
Retinal Physician : May 2019
Technology name [formulation]* for indication [– first/second/third line]*
Neovascular Age-related Macular Degeneration | JEP
Pipeline Report: New entries continue to exceed exits
Chengdu Kanghongs' Phase III ophthalmic agent drops 7 points in AMD
Anti VEFG Agents In Retinal Diseases
Pipeline Report: Despite major approvals, the queue gets longer
Tracking the treatments of tomorrow.
PDF) Profile of conbercept in the treatment of neovascular age-related macular degeneration
More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept | BioSpace
Phase III Trials in Wet AMD—What's Next?
Our Ophthalmic Studies – Cascade Medical Research Institute
Retinal Physician : October 2019
2023: The year of geographic atrophy
Molecules | Free Full-Text | Recent Advances in Age-Related Macular Degeneration Therapies
